03/10/23 9:45 PMNasdaq : ACAD fda approvalAcadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and OlderAcadia Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved DAYBUE™ for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. “Rett syndrome is a profoundly debilitating and complex, rare, neurodevelopmental disorder that presents differently across patients and can lead to an...RHEA-AIneutral
02/27/23 4:05 PMNasdaq : ACAD earningsAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating OverviewAcadia Pharmaceuticals Inc., today announced its financial results for the fourth quarter and full year ended December 31, 2022. NUPLAZID ® delivered net sales of $136.5 million in the fourth quarter of 2022 and $517.2 million for the full year. Both of these analyses found a lower mortality risk in patients with Parkinson’ s disease psychosis treated with...RHEA-AIneutral
02/14/23 4:05 PMNasdaq : ACAD earningsAcadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023Acadia Pharmaceuticals Inc. today announced that it will report fourth quarter and full year 2022 financial results on Monday, February 27, 2023, after the close of the U.S. financial markets. Acadia’ s management team will also host a conference call and webcast on February 27, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.RHEA-AIneutral
02/13/23 4:15 PMNasdaq : ACAD Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Acadia Pharmaceuticals Inc. today announced that on February 10, 2023, the Compensation Committee of Acadia’ s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 310,065 shares of common stock and 97,251 restricted stock units to 19 new employees under Acadia’ s 2023 Inducement Plan. Among such awards was a...RHEA-AIvery positive
01/09/23 9:00 AMNasdaq : ACAD, AVDL managementAcadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and DevelopmentAcadia Pharmaceuticals Inc. announced today the appointment of Dr. Dr. Williamson will lead research and development at Acadia and will serve as a member of the company’ s Executive Management Committee, reporting to Steve Davis, Chief Executive Officer of Acadia. Dr. Williamson will succeed Dr.RHEA-AIvery positive
01/03/23 9:00 AMNasdaq : ACAD Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical AntipsychoticsAcadia Pharmaceuticals Inc. announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’ s disease psychosis treated with NUPLAZID ® compared to other atypical antipsychotics over 12 months and across various subgroups. The robust results were achieved across...RHEA-AIneutral
12/21/22 4:05 PMNasdaq : ACAD conferencesAcadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023Acadia Pharmaceuticals Inc. today announced that it will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question and answer session. Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson 395-3043 media@acadia-pharm.com. Investor Contact: Acadia Pharmaceuticals Inc....RHEA-AIneutral
11/08/22 4:05 PMNasdaq : ACAD conferencesAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesAcadia Pharmaceuticals Inc. today announced that it will participate at the following upcoming investor conferences:. Guggenheim 4 th Annual Immunology and Neurology Day November 14, 2022 in New York, NY. J.P. Morgan Equity Opportunities Forum November 15, 2022 in Miami, FL.RHEA-AIneutral
11/02/22 4:05 PMNasdaq : ACAD earningsAcadia Pharmaceuticals Reports Third Quarter 2022 Financial ResultsAcadia Pharmaceuticals Inc., today announced its financial results for the third quarter ended September 30, 2022. The FDA granted a priority review and assigned a PDUFA action date of March 12, 2023, and informed the company that they are not planning to hold an Advisory Committee meeting. Presented clinical data for trofinetide at medical congresses in...RHEA-AIneutral
10/27/22 4:05 PMNasdaq : ACAD Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) StankovicAcadia Pharmaceuticals Inc. today announced that its President, Srdjan Stankovic, M.D., M.S.P.H., who is responsible for R&D, and Medical and Scientific functions, will retire at the end of the year. A search for a successor to Dr. Stankovic is ongoing. Following his retirement, Dr. Stankovic will provide consulting and advisory services for Acadia on a part-time...RHEA-AIvery positive